Our Guest Speakers
David Bick is an internationally recognized leader in clinical genomics and genomic medicine, with experience in pediatrics, clinical genetics, and molecular genetics. He serves as Principal Clinician for the Newborn Genomes Programme( Generation Study) at Genomics England, where he is helping evaluate the integration of whole genome sequencing into newborn screening across the United Kingdom’ s National Health Service. Previously, Dr. Bick held leadership roles at the Hudson Alpha Institute for Biotechnology and the Medical College of Wisconsin, where he advanced clinical sequencing programs and precision medicine initiatives. His work has contributed to the expansion of genomic sequencing in clinical care.
Katherine Stueland is President and Chief Executive Officer of GeneDx, a leading provider of genomic diagnostics for rare diseases. She oversees one of the world’ s largest rare disease datasets, comprising more than one million exomes and genomes. With over two decades of experience in the life sciences and diagnostics industry, Ms. Stueland previously spent seven years at Invitae, where she helped scale the company into an industry leader. Earlier in her career, she contributed to the development and launch of the first protease inhibitor for HIV / AIDS and the first FDA-approved cancer immunotherapy. Her work reflects a commitment to advancing precision medicine and improving outcomes for patients with rare and genetic diseases.
Moran Snir is Co-Founder and Chief Executive Officer of Nest Genomics, a digital health company building infrastructure to integrate genomic care into routine clinical practice. Its software platform enables health systems to deliver longitudinal, genomics-informed care at scale and incorporate genomic insights into everyday clinical workflows. A serial entrepreneur, Ms. Snir previously co-founded Clear Genetics and has led software teams across diverse healthcare settings. Her work focuses on leveraging technology to expand access to precision medicine, with an emphasis on scalable digital platforms that support clinical decision-making, patient engagement, and the integration of genomics into population health.
Tom DeFay is Deputy Head of Diagnostics Strategy and Development at Alexion, AstraZeneca Rare Disease and Vice Chair of the BeginNGS Consortium. His work focuses on accelerating rare disease diagnosis through whole genome sequencing and AI-driven screening, with the goal of enabling early intervention as a global standard of care. Dr. DeFay has contributed to the development and implementation of large-scale genomic screening programs and collaborates across industry, clinical, and public health sectors to advance equitable access to early diagnosis. His work supports the integration of genomic technologies into routine healthcare systems worldwide.
03